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Science, like the universe itself, is ever expanding. The 
fields of biochemistry, physiology and pharmacology 
are rapidly growing, and radiopharmaceutical chem- 
istry is no exception. In a recent Editorial Dr William 
C. Eckelman briefly reviewed the current status of 
radiopharmaceutical development (Eckelman, 1991). 
The ballots are out and returns are mixed. Radio- 
pharmaceutical chemists have made great strides in 
the development and refinement of methods for 
radiochemical syntheses, but have made little impact 
on clinical Nuclear Medicine. Dr Eckelman ends his 
Editorial with a plaintive plea for more validation of 
radiotracers. 
Dr Eckelman did not go far enough; radiopharma- 
ceutical chemists need to be educated as to what are 
the important questions to which they should be 
devoting their time and talents. We do not need 
radiotracers to tell us where certain high affinity 
binding sites are in anima1 or human tissues; the fields 
of autoradiography and molecular biology are doing 
that just fine, with far greater resolution than we 
can ever hope for. It is not sufficient that new 
radiotracers are “validated” by a lack of specific 
binding after pharmacological pretreatments with 
massive amounts of cold drugs, or after severe neuro- 
chemical lesions in animal models, or in end-stage 
human disease. The answers we seek are not so black 
and white, but rather shades of grey. We need to 
develop sensitive in uiuo measures of biochemical 
parameters which impact on the prevention or thera- 
peutic treatment of human diseases. Nothing less. 
In his Editorial, Bill Eckelman outlines three steps 
in radiotracer development. First, “develop a radio- 
tracer that binds preferentially to a specific site”. 
Second, “determine the sensitivity of the radiotracer 
to a change in biochemistry”. Finally, “find a bio- 
chemical change as a function of a specific disease 
that matches that sensitivity”. Dr Eckelman may 
have put the cart before the horse. The first step in 
a radiopharmaceutical development program should 
be to identify the relevant disease and the needed 
sensitivity (the percent change in any given par- 
ameter) which will be the focus of the study. Fortu- 
nately, more and more diseases are now being defined 
biochemically, with definitions of both the site and 
extent of an abnormal biochemical process. These 
data should be our ticket to the fun-house and our 
guide through the unknown. Admittedly, in many 
disease states the needed sensitivity may not be 
known; a good example is Parkinson’s disease, where 
it is not known exactly what degree of change in the 
striatal dopaminergic system results in progression 
from normal function to symptomatic disease (and 
will this imaginary boundary be the same for all 
subjects?). Even in these cases, however, it might be 
expected that the large scale changes present at 
end-stage disease will not be the primary target of 
in vivo studies, and development of radiopharmaceu- 
ticals with a matching all-or-none sensitivity might be 
of lesser interest. 
One cannot disagree with Dr Eckelman that too 
little time, thought and effort is spent on the analysis 
of the sensitivity of a radiotracer measure, sometimes 
erroneously termed “validation”. But just what is 
“validation”? It depends upon the question being 
asked. If one wishes to know the rate of loss of a 
specific binding site during the course of a neuro- 
degenerative disease, a sensitivity to S-10% changes 
in biochemistry might be required for medical utility. 
If one wishes, on the other hand, to differentiate 
between pathologies involving two optional but large 
scale changes in biochemistry, or simply the location 
of a large biochemical change, far less sensitivity 
might be perfectly acceptable. 
So what kinds of sensitivity testing should be 
pursued? A favorite of many is the correlation 
between in vivo values, such as tissue ratios, B,,,,,, 
binding potential, volume of distribution or other 
parameter and in vitro measures of the same binding 
site or enzyme site densities as measured in different 
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regions of an organ. Unfortunately, good in vitro- 
in uivo correlations do not necessarily equate with 
successful clinical radiopharmaceuticals. We have, in 
the past few years prepared numerous potential 
PET radioligands for which adequate to quite good 
in vivo-in vitro correlations can be made (Haka and 
Kilbourn, 1989; Kilbourn et al., 1990a,b, 1991; Lee 
et al., 1991; Mulholland et al., 1992; Wieland et al., 
1990; Rosenspire et aI., 1990). However, in most cases 
the dynamic range of the in vivo measured values are 
only a fraction of the dynamic range for the in vitro 
values, and the sensitivity of such radiotracers to 
clinically relevant changes of in oivo biochemistry 
remains unknown. But are these radiotracers “vali- 
dated” by the in viuo-in vitro correlation, and if so, 
what are they useful for? Do the in vitro values even 
represent the functional range of such binding sites 
in the intact organism, and do the in vitro values 
represent the optimal “image” one might obtain from 
an in vivo study resplendent with secondary binding 
sites and generalized non-specific binding? 
As an example, we have considerable experience 
with [‘*F]GBR 12909, which exhibits in vivo striatum/ 
cerebellum ratios (str/cer, a crude measure of specific 
binding) which do not even approach the values that 
might be calculated from the in vitro concentrations 
of dopamine uptake sites in these tissues (given that 
it is difficult to calculate a precise ratio, as there are 
no DA uptake sites in cerebellum). Some investi- 
gators are willing to explain these results through 
secondary binding to sigma receptors or a cyto- 
chrome P450IIDl enzyme site (Niznik et al., 1990). 
Surprisingly, the cocaine analog CFT (WIN 35,428), 
also a dopamine uptake site radioligand, exhibits the 
exact same behavior: relatively poor in vivo str/cer 
ratios (< 5) for [“C]CFT (Madras et al., 1991) despite 
exceptionally high values from the in vitro [‘H]CFT 
autoradiography in the same species (Kaufman et al., 
1991). Some of this difference can be attributed to the 
problems of partial volume averaging in imaging of 
monkeys, but should the rest be attributed to CFT 
binding to other high affinity sites such as the 
P450IIDl sites, for which cocaine has been reported 
to have a high (74 nM) affinity (Tyndale et al., 1991), 
or possibly also the sigma receptor? Given the long 
list of compound types which show affinity for the 
sigma receptor (Koe et al., 1991), maybe the question 
should be reversed; what does not bind to the sigma 
receptor? And, really, does it matter? Even more to 
the point, if we are to utilize a radiotracer to evaluate 
a specific binding site in specific tissue regions, should 
we even be concerned with the behavior of that 
radioligand in tissues or regions uninvolved in the 
physiology or pathology in question? As one begins 
to ponder these questions, “validation” by compari- 
son of in vivo and in vitro regional organ distributions 
seems incomplete. 
The second standard method of “validation” is 
determining the dose-response curve of radioligand 
binding in animals, using competition for sites by 
doses of the identical or pharmacologically equival- 
ent but structurally different drugs. Is this sufficient? 
Such studies demonstrate that measured values of in 
viuo binding sites can be reduced by competing drugs, 
but are such pharmacological challenges the equival- 
ent of the functional changes evidenced during a 
disease process? Probably not; biochemistry is very 
complex, and it is almost inconceivable that changes 
in one aspect such as a number of binding sites or 
enzyme molecules are not accompanied by other 
changes in biochemistry. Proving that a drug treat- 
ment “mimics” a disease is challenging, and one must 
question whether a dose-response curve is a “vali- 
dation” of the usefulness of the radiotracer in the 
intended disease. 
Should tracers be “validated” in animal models of 
human diseases, or even better, through clinical 
trials? The last is a poor alternative; the costs and 
ethics of radiotracer evaluation in humans can be 
prohibitive. What about animal models? This may be 
an under-utilized methodology in radiopharrnaceuti- 
cal development, as there are certainly a plethora of 
lesion (Conn, 1991) behavioral and genetic animal 
models for human diseases, even for such diseases as 
senile dementia (La1 and Forster, 1991). In the same 
issue which held Dr Eckelman’s Editorial, we pub- 
lished one of our attempts in this area, utilizing 
the degeneration and subsequent regeneration of 
dopaminergic terminals in MPTP-treated mice as 
what might be envisioned as a “reverse” mode1 of 
Parkinson’s disease (Kilbourn et al., 1991). Relatively 
crude measures of in vivo specific binding of [“F]GBR 
13119 (a dopamine uptake blocker and putative 
neuronal marker) in mouse striatum increased with 
recovery of the animals. Remarkable correlations 
with published recoveries of tissue dopamine 
(r* = 0.98) and tyrosine hydroxylase enzymatic 
activity (TH: r* = 0.99) measured in vitro for the same 
animal model could be made (Fig. I.) (Donnan et al., 
1987; Nishi et al., 1989), although such were not 
reported in that publication. Is this a more proper 
way of “validation”? The discerning reader will note 
that the dynamic range for [‘*F]GBR 13119 binding 
is larger than the dynamic range for TH enzymatic 
activity, but less than the dynamic range for endogen- 
ous dopamine levels. Which are the proper in vitro 
data to use in such correlations, and which corre- 
lation is correct for modeling Parkinson’s disease in 
humans? Which in vitro measure-tyrosine hydroxyl- 
ase, which is perhaps a measure of surviving neurons, 
or dopamine, which might be a better measure of the 
functional status of the surviving neurons-would be 
important in the development (and perhaps evalu- 
ation through in vivo PET studies) of therapeutic drug 
strategies for prevention or amelioration of Parkin- 
sonian symptoms? As Dr Eckelman points out, even 
such encouraging results in animals can be hard 
to translate to clinical efficacy, but perhaps more 
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Fig. 1. Correlations of in vivo specific binding of [‘8F]GBR 
13119 with in vitro measures of endogenous dopamine 
concentrations (A) and tyrosine hydroxylase enzymatic ac- 
tivities (B) in the striatum of mice at selected times following 
systemic MPTP treatment. In vivo data frorn Kilbourn et al. 
11991) and in vitro data from Donnan et al. (1987) and Nishi . I 
et al. (1989). ~ ’ 
Development of new radiopharmaceuticals has 
become, if anything, even more complicated and 
challenging: neurochemistry, pharmacology and 
molecular biology have spawned a whole new and 
sometimes bewildering neurochemical landscape. 
There are five muscarinic receptors, and at least five 
dopamine receptors; who knows how many subtypes 
of subtypes of serotonin receptor may eventually 
surface. Glutamate pharmacology, once neatly 
wrapped up as NMDA, kainate and quisqualate 
receptors, is exploding: there is at least one new 
receptor type not linked to an ion channel (metabo- 
tropic receptor), and possibly multiple subtypes of 
each of these receptor types (Aizawa et al., 1991; 
Vecil et al., 1991; Sakurai et al., 1991) There may be 
multiple forms of tyrosine hydroxylase; the func- 
tional significance of this finding still eludes us 
(Melchitz et al., 1991). Armed only with a radio- 
chemical, an imaging device and a pharmacokinetic 
mode1 (Carson, 1991), are we too presumptuous to 
think we can ever figure out nature’s complexities? 
Do we make too many new radiochemicals with 
too little evaluation of their applicability? Perhaps; 
certainly a disproportionate share of the resources is 
devoted to synthesis of new variants of radiopharma- 
ceuticals that have not been fully evaluated in the first 
place. But we may also analyze ourselves into a 
corner, and suffer paralysis of both thought and 
action. The synthesis of new radiotracers and their 
evaluation through in uivo-in vitro correlations, 
dose-response analyses and animal models will con- 
tinue as our route to new clinical radiopharmaceuti- 
cals. So until such time as we have all of the answers 
on a theoretical basis, much has been and will 
continue to be learned from the experimental 
approach. 
Acknowledgement-This work was supported by USPHS 
grants NS15655 and MH4761 I. 
References 
Aizawa H., Kwak S., Ishida M. and Shinozaki H. (1991) 
Pharmacological evidence suggesting multiplicity of 
kainate receptors in the rat central nervous system. Sot. 
Neurosci. Abstr. 17, 1538. 
Carson R. E. (1991) The development and application of 
mathematical models in nuclear medicine. J. Nucl. Med. 
32, 2206. 
Conn M. P. (1991) Lesions and transplantation. In Methods 
in Neuroscience, Vol. 7. Academic Press, New York. 
Donnan G. A., Kaczmarczyk S. J., McKenzie J. S., Rowe 
P. J., Kalnins R. M. and Mendelsohn F. A. 0. (1987) 
Regional and temporal effects of I-methyl-4-phenyl- 
1,2,3,6_tetrahydropyridine on dopamine uptake sites in 
mouse brain. J. Neurol. Sci. 81, 261. 
Eckelman W. C. (1991) The status of radiopharmaceutical 
research. Nucl. Med. Biol. 18, iii. 
Haka M. S. and Kilboum M. R. (1989) Synthesis and 
regional brain distribution of [“Clnisoxetine, a norepi- 
nephrine uptake inhibitor. Nucl. Med. Biol. 16, 771. 
Kaufman M. J., Spealman R. D. and Madras B. K. (1991) 
Distribution of cocaine recognition sites in monkey brain: 
I. In uirro autoradiography with [‘H]CFT. Synapse 9, 
177. 
Kilbourn M. R., Mulholland G. K., Sherman P. S. and 
Pisani T. (1991) In vivo binding of the dopamine uptake 
inhibitor [‘*FjGBR 13119 in MPTP-treated C57BL/6 
mice. Nucl. Med. Biol. 18, 803. 
Kilboum M. R., Pavia M. R. and Gregor V. E. (1990a) 
Synthesis of fluorine-18 labelled GABA uptake inhibitors. 
Appl. Radial. Isot. 41, 823. 
Kilboum M. R., Jung Y.-W., Haka M. S., Gildersleeve 
D. L., Kuhl D. E. and Wieland D. M. (1990b) Mouse 
brain distribution of a carbon-11 labeled vesamicol 
derivative: presynaptic marker of cholinergic neurons. 
Li/e Sci. 47, 1955. 
Koe B. K., Fox C. B. and Lebel L. A. (1991) Structural 
classes of compounds with potent affinity for brain sigma 
binding sites. Sot. Neurosci. Abstr. 17, 332. 
La1 H. and Forster M. J. (1991) Autoimmune mice as 
models for discovery of drugs against age-related demen- 
tia. Dru.a Dev. Res. 24, 1. 
Lee K. S.,-Frey K. A., Koeppe R. A., Mulholland G. K., 
Kilbourn M. R. and Kuhl D. E. (1991) In vivo auantifi- 
cation of muscarinic cholinergic receptors in human 
aging: positron tomography suggests preferential cortical 
decline. J. Cereb. Bid Flow Metab. 11, S790. 
Madras B. K., Fahey M. A., Kaufman M. J., Spealman 
R. D., Schumacher J., Isacson O., Brownell A. L., 
Brownell G. L. and Elmaleh D. R. (1991) Cocaine 
606 Editorial 
receptor probes in human and nonhuman primate brain: 
in vifro characterization and in uivo imaging. Sot. Neuro- 
sci. Abstr. 17, 190. 
Melchitz D. S., Scolieri M. J., Haycock J. W. and Lewis 
D. A. (1991) Expression of different forms of tyrosine 
hydroxylase in monkey and human brain. Sot. Neurosci. 
Abstr. 17, 980. 
Mulholland G. K., Otto C. A., Jewett D. M., Kilbourn 
M. R., Koeppe R. A., Sherman P. S., Petry N. A., 
Carey J. A.,.Atkinson E. R., Archer S., Frey K. A. 
and Kuhl D. E. (1992) Svnthesis. biodistribution. 
dosimetry, metabolism and monkey’ PET studies of 
carbon-l 1 labeled (+)-2a-tropanyl benzilate, a central 
muscarinic receptor imaging agent. J. Nucl. Med. 33, 
423. 
Nishi K., Kondo T. and Narabayashi H. (1989) Differences 
in recovery patters of striatal dopamine content, tyrosine 
hydroxylase activity and total biopterin content after 
I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
administration: a comparison of young and older mice. 
Bruin Res. 489, 151. 
Niznik H. B., Tyndale R. F., Sallee F. R., Gonzalez F. J., 
Hardwick J. P., Inaba T. and Kalow W. (1990) Archs 
Biochem. 276, 424. 
Rosenspire K. C., Haka M. S., Van Dort M. E., Jewett 
D. M., Gildersleeve D. L., Schwaiger M. and Wieland 
D. M. (1990) Synthesis and preliminary evaluation of 
carbon-l 1 mefa-hydroxyephedrine: a false neurotransmit- 
ter for heart neuronal imaging. J. Nucl. Med. 31, 1328. 
Sakurai S. Y., Penney J. B. and Young A. B. (1991) 
Regionally distinct NMDA receptor subtypes distin- 
guished by [‘H]MK-801 binding. Sot. Neurosci. Abstr. 17, 
1534. 
Tyndale R. F., Sunahara R., Inaba T., Kalow W., Gonzalez 
F. J. and Niznik H. B. (1991) Neuronal cytochrome 
P450IIDl (Debrisoauineisnarteine-tvne): notent inhi- 
bition of activity by (-)-cocaine and %cieoiide sequence 
identity to human hepatic P450 gene CYP2D6. Molec. 
Pharm. 40, 63. 
Vecil G. G., Li P. P. and Warsh J. J. (1991) Evidence for 
metabotropic excitatory amino acid receptor hetero- 
geneity: developmental and brain regional studies. Sot. 
Neurosci. Abstr. 17, 70. 
Wieland D. M., Rosenspire K. C., Hutchins G. D., Van 
Dort M., Rothley J. M., Mislankar S. G., Lee H. T., 
Massin C. C., Gildersleeve D. L., Sherman P. S. and 
Schwaiger M. (1990) Neuronal mapping of the heart with 
6-[‘*F]fluorometaraminol. J. Med. Chem. 33, 956. 
